Booster vaccines reduced the risk of COVID‑19-related hospitalization and death, according to a new study of over 3 million adults who had the autumn 2022 vaccine in England. The research, led by the ...

Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.

Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivals’ setbacks. Click here ...

President Trump on Thursday unveiled his lower-cost drug platform TrumpRx, touting it as “one of the most transformative ...

President Donald Trump has found himself in an odd juxtaposition as traditional allies are pushing back on his Most Favored Nation (MFN) plan to reduce the price of prescription drugs.  < | As ...

An interim analysis of safety data showed no increased risk associated with Pfizer’s respiratory syncytial virus vaccine when ...

PFE stock decreased 30.0% from a peak of $40.71 on January 23, 2020, to $28.49 on March 23, 2020, compared to a ...

Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Learn more on PFE stock here.

Entera Bio Ltd. (NASDAQ:ENTX) has appointed seasoned pharmaceutical executive Geno J. Germano as Chairman of the Board, ...

The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday.

An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.

Chinese pharmaceutical companies that as a group chalked up record outbound licensing agreements with international industry ...